Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Follistatin 344 vs Sermorelin
An educational, source-based comparison of Follistatin 344 and Sermorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Myostatin-binding protein fragment researched for muscle growth.
A naturally occurring glycoprotein that binds and neutralizes myostatin and activin, releasing the natural brake on skeletal muscle growth in preclinical models.
- Muscular dystrophy models
- Skeletal muscle hypertrophy
- Age-related sarcopenia (preclinical)
- • Off-target effects on activin signaling (reproductive, cardiac) are a concern.
- • Not FDA-approved; banned by WADA.
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Follistatin 344 | Follistatin gene delivery enhances muscle growth and strength | Science Translational Medicine | 2009 | Demonstrated durable hypertrophy in primate models. |
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
Side-effect & safety grid
- Off-target effects on activin signaling (reproductive, cardiac) are a concern.
- Not FDA-approved; banned by WADA.
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Follistatin 344 vs Sermorelin — Key differences
- Class: Follistatin 344 is classified as Muscle · Myostatin Inhibition, while Sermorelin is Growth Hormone Axis.
- Primary research focus: Follistatin 344 — muscular dystrophy models; Sermorelin — adult gh deficiency.
- Tag: Muscle vs Growth hormone.